<DOC>
	<DOCNO>NCT01535027</DOCNO>
	<brief_summary>Increased bone formation absence accelerate resorption result mark anabolic response teriparatide ( TPTD ) early phase treatment initiation . Months later , due couple mechanism , sustain increase bone formation ongoing anabolic effect accompany significantly increase bone resorption well . Antiresorptives influence balance bone formation resorption . Therefore investigator aim investigate effect addition antiresorptives second half TPTD cycle resorption already also markedly elevate .</brief_summary>
	<brief_title>Combined Administration Teripapartide Antiresorptive Agents Postmenopausal Osteoporosis</brief_title>
	<detailed_description>We prospectively randomize 125 postmenopausal woman 9 month TPTD treatment three different open-label group another 9 month : either alendronate ( ALN , 70 mg/week ) , raloxifene ( RAL , 60 mg/day ) medication ( TPTD mono ) top ongoing TPTD treatment . All subject receive daily supplementation 1000mg calcium 800 IU vitamin D. Serum level intact amino terminal propeptide type I procollagen ( PINP ) type 1 collagen cross-linked C-telopeptide ( CTX ) well DXA measurement spine , total hip femoral neck BMD evaluate TPTD treatment initiation , baseline randomization antiresorptive therapy well 3 9 month combination treatment.Volumetric BMD value also determine .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Ambulatory postmenopausal woman least 55 year age Patients `` unsatisfactory clinical response previous antiresorptive therapy '' accord national reimbursement criterion Austria ( either new clinical radiographic fragility fracture ≥ 2 year and/or accelerate bone loss ≥ 3.5 % /year antiresorptive treatment ; discontinuation oral antiresorptive treatment due sideeffects substantial risk osteoporotic fracture define TScore ≤ 2.5 ≥ 2 clinical risk factor accord FRAX™algorithm ) consequently start teriparatide treatment Patients treat teriparatide ( 20 ug/day ) currently since 9 month postmenopausal osteoporosis Lumbar spine , femoral neck , total hip evaluable dual energy x ray absorptiometry ( DXA ) Normal clinically nonsignificant abnormal laboratory value ( define investigator ) Without language barrier , cooperative , expect return followup procedure , give informed consent enter study inform medication procedure use study History bone metabolic disease , Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis , hyperparathyroidism ( uncorrected ) , intestinal malabsorption History malignant neoplasm prior 5 year , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . If malignant neoplasm ever diagnose , patient must presently free disease History nephrolithiasis urolithiasis prior 2 year . Patients document history nephro urolithiasis must appropriate imaging procedure within prior 6 month , , intravenous pyleogram ( IVP ) , supine radiograph kidney ureter bladder , renal ultrasound , must document absence stone Abnormal thyroid function time prior 6 month . Patients chronic hypothyreosis adequate substitution therapy permit Active liver disease ( liver enzymes three time upper limit normal ) clinical jaundice Significantly impair renal function . This define serum creatinine &gt; 1.8 mg/dL Treatment bone active agent teriparatide prior 9 month</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>teriparatide</keyword>
	<keyword>alendronate</keyword>
	<keyword>raloxifene</keyword>
	<keyword>bone mineral density</keyword>
</DOC>